New England Journal of Medicine· 2014Q1

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Tamás Masszi et al.

1,327citations
Q1SCImago
2014year

Short summary

Adding carfilzomib to lenalidomide and dexamethasone significantly improved progression-free survival (median 26.3 vs. 17.6 months) in relapsed multiple myeloma patients (n=792).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine